Immunotherapy

Immunotherapy Guidelines

ACAAI/AAAAI Immunotherapy GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/91852

Contents of this Issue

Navigation

Page 25 of 25

Table 7. Grading System for Recommendations Category/Grade Definition Level of Evidence Ia Ib IIa IIb III IV Evidence from meta-analysis of randomized controlled trials Evidence from at least one randomized controlled trial Evidence from at least one controlled study without randomization Evidence from at least one other type of quasi-experimental study Evidence from non-experimental descriptive studies, such as comparative studies Evidence from expert committee reports or opinions or clinical experience of respected authorities or both Strength of Recommendation A B C D E Directly based on category I evidence Directly based on category II evidence or extrapolated recommendation from category I evidence Directly based on category III evidence or extrapolated recommendation from category I or II evidence Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence Based on consensus of the Joint Task Force on Practice Parameters Abbreviations ACE, angiotensin converting enzyme; FDA, Food and Drug Administration; FEV1 forced expiratory volume in one second; LLR, Large local reactions; PEF, Peak expiratory flow rate measurement; PNU, protein nitrogen unit; SLIT, sublingual immunotherapy; VIT, venom immunotherapy , Source Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Immunotherapy: A practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. Epub 2010 Dec 3. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. PRINTCODE 5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2011 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of Immunotherapy - Immunotherapy Guidelines